WO1991009958A3 - Procede d'acheminement de molecules dans des cellules eukaryotes - Google Patents

Procede d'acheminement de molecules dans des cellules eukaryotes Download PDF

Info

Publication number
WO1991009958A3
WO1991009958A3 PCT/US1990/007607 US9007607W WO9109958A3 WO 1991009958 A3 WO1991009958 A3 WO 1991009958A3 US 9007607 W US9007607 W US 9007607W WO 9109958 A3 WO9109958 A3 WO 9109958A3
Authority
WO
WIPO (PCT)
Prior art keywords
eukaryotic cells
delivering molecules
delivering
interest
molecule
Prior art date
Application number
PCT/US1990/007607
Other languages
English (en)
Other versions
WO1991009958A2 (fr
Inventor
Alan Frankel
Carl Pabo
Original Assignee
Whitehead Biomedical Inst
Univ Johns Hopkins Med
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Whitehead Biomedical Inst, Univ Johns Hopkins Med filed Critical Whitehead Biomedical Inst
Priority to AU71829/91A priority Critical patent/AU658818B2/en
Priority to JP91503306A priority patent/JPH05505102A/ja
Priority to EP91903111A priority patent/EP0506884B1/fr
Priority to DE69028412T priority patent/DE69028412T2/de
Priority to CA002071214A priority patent/CA2071214C/fr
Publication of WO1991009958A2 publication Critical patent/WO1991009958A2/fr
Publication of WO1991009958A3 publication Critical patent/WO1991009958A3/fr
Priority to GR960402831T priority patent/GR3021474T3/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/71—Fusion polypeptide containing domain for protein-protein interaction containing domain for transcriptional activaation, e.g. VP16
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/80—Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Plant Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Procédé d'acheminement d'une molécule d'intérêt, laquelle est une protéine, un peptide, un oligonucléotide ou un médicament dans la cellule, notamment dans le noyau de la cellule, et molécule de conjugué de protéine Tat d'intérêt, lequel est utile dans le procédé. Le procédé et le conjugué sont utiles à des fins diagnostiques, prophylactiques et thérapeutiques.
PCT/US1990/007607 1989-12-21 1990-12-21 Procede d'acheminement de molecules dans des cellules eukaryotes WO1991009958A2 (fr)

Priority Applications (6)

Application Number Priority Date Filing Date Title
AU71829/91A AU658818B2 (en) 1989-12-21 1990-12-21 Method of delivering molecules into eukaryotic cells using tat protein conjugate
JP91503306A JPH05505102A (ja) 1989-12-21 1990-12-21 真核細胞の中に分子を配達する方法
EP91903111A EP0506884B1 (fr) 1989-12-21 1990-12-21 Procede d'acheminement de molecules dans des cellules eukaryotes
DE69028412T DE69028412T2 (de) 1989-12-21 1990-12-21 Verfahren zum transport von molekülen in eukaryotenzellen
CA002071214A CA2071214C (fr) 1989-12-21 1990-12-21 Methode d'administration de molecules dans les cellules eucaryotes
GR960402831T GR3021474T3 (en) 1989-12-21 1996-10-24 Method of delivering molecules into eukaryotic cells

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US45445089A 1989-12-21 1989-12-21
US454,450 1989-12-21

Publications (2)

Publication Number Publication Date
WO1991009958A2 WO1991009958A2 (fr) 1991-07-11
WO1991009958A3 true WO1991009958A3 (fr) 1991-08-08

Family

ID=23804657

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1990/007607 WO1991009958A2 (fr) 1989-12-21 1990-12-21 Procede d'acheminement de molecules dans des cellules eukaryotes

Country Status (10)

Country Link
EP (1) EP0506884B1 (fr)
JP (1) JPH05505102A (fr)
AT (1) ATE142266T1 (fr)
AU (1) AU658818B2 (fr)
CA (1) CA2071214C (fr)
DE (1) DE69028412T2 (fr)
DK (1) DK0506884T3 (fr)
ES (1) ES2091916T3 (fr)
GR (1) GR3021474T3 (fr)
WO (1) WO1991009958A2 (fr)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5652122A (en) * 1989-12-21 1997-07-29 Frankel; Alan Nucleic acids encoding and methods of making tat-derived transport polypeptides
US6316003B1 (en) 1989-12-21 2001-11-13 Whitehead Institute For Biomedical Research Tat-derived transport polypeptides
US5804604A (en) * 1989-12-21 1998-09-08 Biogen, Inc. Tat-derived transport polypeptides and fusion proteins
NZ239893A (en) * 1990-09-25 1993-11-25 Hoechst Japan A method for introducing a foreign dna into a cell
US5633230A (en) * 1990-10-24 1997-05-27 Allelix Biopharmaceuticals, Inc. Treatment of cytomegalovirus infection
WO1993012234A1 (fr) * 1991-12-13 1993-06-24 Sri International Reactifs antiviraux a base de proteines de liaison de l'arn
EP2000536A3 (fr) 1992-08-21 2010-06-30 Biogen Idec MA, Inc. Polypeptides de transport à dérivés de tat
IL106760A (en) * 1992-08-25 1999-12-31 Miles Inc Nuclear Acid Protein Hybrid Structure for Transferring Nucleic Acid from External Source to Cell and Target Nucleus
US7001759B1 (en) 1993-01-26 2006-02-21 The Trustees Of The University Of Pennsylvania Compositions and methods for delivery of genetic material
EP1473369B1 (fr) 1993-01-26 2009-01-07 The Trustees of the University of Pennsylvania (a corporation of Pennsylvania) Compositions et procédés d'administration de matières génétiques
ES2249760T3 (es) * 1993-01-26 2006-04-01 The Trustees Of The University Of Pennsylvania (A Corporation Of Pennsylvania) Composiciones y procedimientos de administracion de materias geneticas.
US5795587A (en) 1995-01-23 1998-08-18 University Of Pittsburgh Stable lipid-comprising drug delivery complexes and methods for their production
ES2210761T3 (es) 1997-05-21 2004-07-01 The Board Of Trustees Of The Leland Stanford Junior University Composicion y procedimiento para mejorar el transporte a traves de las membranas biologicas.
US5891994A (en) 1997-07-11 1999-04-06 Thymon L.L.C. Methods and compositions for impairing multiplication of HIV-1
US6348185B1 (en) 1998-06-20 2002-02-19 Washington University School Of Medicine Membrane-permeant peptide complexes for medical imaging, diagnostics, and pharmaceutical therapy
US8038984B2 (en) 1998-06-20 2011-10-18 Washington University Membrane-permeant peptide complexes for treatment of sepsis
US7306784B2 (en) 1998-06-20 2007-12-11 Washington University Membrane-permeant peptide complexes for medical imaging, diagnostics, and pharmaceutical therapy
US6589503B1 (en) 1998-06-20 2003-07-08 Washington University Membrane-permeant peptide complexes for medical imaging, diagnostics, and pharmaceutical therapy
US6730293B1 (en) 1999-08-24 2004-05-04 Cellgate, Inc. Compositions and methods for treating inflammatory diseases of the skin
MXPA02001857A (es) 1999-08-24 2003-07-14 Cellgate Inc Composiciones y metodos para incrementar la entrega de drogas a traves y dentro de tejidos epiteliales.
US7229961B2 (en) 1999-08-24 2007-06-12 Cellgate, Inc. Compositions and methods for enhancing drug delivery across and into ocular tissues
US6669951B2 (en) 1999-08-24 2003-12-30 Cellgate, Inc. Compositions and methods for enhancing drug delivery across and into epithelial tissues
US6399067B1 (en) 2000-04-28 2002-06-04 Thymon L.L.C. Methods and compositions for impairing multiplication of HIV-1
KR100379578B1 (ko) * 2000-07-26 2003-04-08 최수영 세포침투성 티에이티-씨3 트랜스페라제 융합단백질, 이융합단백질의 발현벡터 및 티에이티-씨3 트랜스페라제를이용한 로 단백질의 생리적 기능 분석방법
KR100379577B1 (ko) * 2000-07-26 2003-04-08 최수영 세포침투성 티에이티 - 인간 글루탐산 탈수소효소 융합단백질, 이 융합단백질을 코딩하는 재조합폴리뉴클레오타이드, 이 융합단백질의 발현벡터 및 이융합단백질을 세포 내로 도입하는 방법
CA2437983C (fr) 2001-02-16 2011-10-25 Cellgate, Inc. Transporteurs comportant des fractions d'arginine espacees
JP2003009883A (ja) * 2001-07-05 2003-01-14 Mitsubishi Pharma Corp マスト細胞の細胞死誘発剤
KR100495138B1 (ko) * 2001-07-31 2005-06-14 학교법인 한림대학교 식물세포 투과 도메인-화물분자 복합체
DE10212867B4 (de) * 2002-03-22 2005-07-21 Hans Prof. Dr. Wolf Verwendung Harnstoff-adjuvierter Polypeptide zur Diagnose, Prophylaxe und Therapie
KR100472939B1 (ko) * 2002-05-24 2005-03-18 학교법인 한림대학교 세포침투성 티에이티-피리독살 카이네이즈 융합단백질 및그 용도
WO2004009665A2 (fr) 2002-07-19 2004-01-29 The Regents Of The University Of California Dendrimeres servant de translocateurs moleculaires
KR100472937B1 (ko) * 2002-07-25 2005-03-10 학교법인 한림대학교 세포침투성 티에이티-사이토신 디아미네이즈 융합단백질및 그 용도
US7183066B2 (en) * 2002-09-27 2007-02-27 Allergan, Inc. Cell-based fluorescence resonance energy transfer (FRET) assays for clostridial toxins
US7563437B2 (en) 2005-02-15 2009-07-21 Thymon, Llc Methods and compositions for impairing multiplication of HIV-1
WO2006094200A2 (fr) * 2005-03-03 2006-09-08 The Trustees Of Boston College Procede pour obtenir une localisation desiree destinee a l'imagerie cellulaire avec l'utilisation de peptidoconjugues
US7935816B2 (en) 2007-10-25 2011-05-03 Gene Tools, Llc Molecular transporter compositions comprising dendrimeric oligoguanidine with a triazine core that facilitate delivery into cells in vivo
EP2618829B1 (fr) 2010-09-22 2019-05-01 The Regents of the University of Colorado, a body corporate Smad7 pour le traitment de la mucite orale ou du psoriasis
SG11201507045TA (en) 2013-03-08 2015-10-29 Univ Colorado Regents Ptd-smad7 therapeutics
KR101835554B1 (ko) 2014-06-24 2018-04-19 서울대학교 산학협력단 C/ebp를 포함하는 유도성 t 조절세포 분화촉진 또는 안정화 조성물 및 방법
CA3061738A1 (fr) 2017-04-28 2018-11-01 Auckland Uniservices Limited Methodes de traitement et nouvelles constructions
CN112236159B (zh) * 2018-05-03 2024-06-11 犹他大学研究基金会 Oca-b肽缀合物和治疗方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0243204A2 (fr) * 1986-04-24 1987-10-28 Cetus Oncology Corporation Système infectieux pour la libération de médicaments
WO1988005077A1 (fr) * 1986-12-29 1988-07-14 Battelle Memorial Institute Procede pour modifier le metabolisme de cellules eucaryotes lors de l'incorporation de sequences etrangeres d'acides nucleique s au moyen d'un vecteur d'internalisation
EP0388758A1 (fr) * 1989-03-16 1990-09-26 BOEHRINGER INGELHEIM INTERNATIONAL GmbH Conjugé protéine-polycation

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0243204A2 (fr) * 1986-04-24 1987-10-28 Cetus Oncology Corporation Système infectieux pour la libération de médicaments
WO1988005077A1 (fr) * 1986-12-29 1988-07-14 Battelle Memorial Institute Procede pour modifier le metabolisme de cellules eucaryotes lors de l'incorporation de sequences etrangeres d'acides nucleique s au moyen d'un vecteur d'internalisation
EP0388758A1 (fr) * 1989-03-16 1990-09-26 BOEHRINGER INGELHEIM INTERNATIONAL GmbH Conjugé protéine-polycation

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Cell, vol. 55, 23 December 1988, Cell Press A.D. Frankel et al.: "Cellular uptake of the tat proteine from human immuno-deficiency virus", pages 1189-1193 *
Cell. Mol. Biol., vol. 28, no. 1, 1982 Pergamon Press Ltd (GB) J.C. Stavridis et al.: "Use of transferrin as a gene-carrier to the erythroid cells of the marrow", pages 15-18 *
Patents Abstracts of Japan, vol. 12, no. 344 (C-528)(3191), 16 September 1988; & JP-A_63102682 (MEDEISA SHINYAKU K.K.) 7 May 1988 *

Also Published As

Publication number Publication date
ATE142266T1 (de) 1996-09-15
CA2071214A1 (fr) 1991-06-22
AU7182991A (en) 1991-07-24
DK0506884T3 (da) 1996-11-04
DE69028412T2 (de) 1997-03-27
AU658818B2 (en) 1995-05-04
EP0506884B1 (fr) 1996-09-04
ES2091916T3 (es) 1996-11-16
GR3021474T3 (en) 1997-01-31
EP0506884A1 (fr) 1992-10-07
CA2071214C (fr) 2006-06-06
WO1991009958A2 (fr) 1991-07-11
DE69028412D1 (de) 1996-10-10
JPH05505102A (ja) 1993-08-05

Similar Documents

Publication Publication Date Title
WO1991009958A3 (fr) Procede d'acheminement de molecules dans des cellules eukaryotes
CA2193337A1 (fr) Composes de type 1-phenyl-2-dimethylaminomethylcyclohexan-1-o1, ingredients pharmaceutiques actifs
CA2194393A1 (fr) Telomerase mammifere
WO1995007992A3 (fr) Decarboxylase d'acide glutamique clonee
WO2000003683A3 (fr) Complexes d'acides nucleiques encapsules dans des liposomes
IL115199A (en) Composition comprising a polynucleic acid molecule in a liposome and method using said composition
WO1998055495A3 (fr) Oligonucleotides immunostimulateurs, compositions correspondantes et leurs procedes d'utilisation
NZ326092A (en) Immunostimulatory composition and method
CA2066204A1 (fr) Gene de la mucoviscidose
AU1926899A (en) Exploiting genomics in the search for new drugs
AU4552097A (en) 7alpha-(epsilon-aminoalkyl)estratrienes, process for preparing the same, pharmaceutical preparations containing said 7alpha-(epsilo-aminoalkyl)estratrienes and their use for preparing medicaments
WO1996001614A3 (fr) Composant d'arn de la telomerase
HUP9800049A3 (en) Amino acid compositions and use thereof in clinical nutrition, and use of the said amino acids for preparing pharmaceutical compns. for the diminution of tnf
AU716500B2 (en) Nucleic acid constructs for the cell cycle-regulated expression of genes, cells containing such constructs and their use for preparing drugs
EP0744408A3 (fr) Protéine d'ob et son ADN
CA2199832A1 (fr) Beta-globine active contre la drepanocytose, preparations et procedes pour traiter cette maladie
AU7758598A (en) Stable pharmaceutical administration forms of peptides, proteins and nucleic acids
WO1994025590A3 (fr) Thrichohyaline et transglutaminase-3 et procedes d'utilisation
AU4416189A (en) Therapeutic and diagnostic methods using soluble t cell surface molecules
CA2242750A1 (fr) Anticorps presentant une charge positive nette reduite
CA2441535A1 (fr) Techniques d'apport de molecules d'acides nucleiques dans des cellules et evaluation de cet apport
AU6113098A (en) Compositions for treatment of disorders involving programmed cell death
WO2000043510A3 (fr) Molecules d'acides nucleiques et polypeptides d'activateurs de ras, et techniques d'emploi
EP0372862A3 (fr) Protéine se liant à la cyclosporine et son utilisation dans un test d'analyse de cyclosporine biologiquement active
WO1997023607A3 (fr) Presentation d'antigenes, introduits dans les cellules par stimulation de la macropinocytose

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU CA FI JP NO

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FR GB GR IT LU NL SE

AK Designated states

Kind code of ref document: A3

Designated state(s): AU CA FI JP NO

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK ES FR GB GR IT LU NL SE

WWE Wipo information: entry into national phase

Ref document number: 2071214

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 1991903111

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1991903111

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 1991903111

Country of ref document: EP